What Was the Federal Zantac MDL?
A multidistrict litigation (MDL) is a federal procedural device that consolidates cases involving similar claims and common factual questions from multiple federal courts into one court for coordinated pretrial proceedings. In re: Zantac (Ranitidine) Products Liability Litigation (MDL No. 2924) was consolidated in the U.S. District Court for the Southern District of Florida before the Honorable Robin L. Rosenberg. At its peak, the MDL included tens of thousands of cases from plaintiffs across the country who alleged that Zantac caused their cancer. The MDL was established to manage the vast volume of litigation efficiently and to resolve common legal and scientific questions — particularly the threshold question of general causation — on behalf of all plaintiffs in the federal system.
The Daubert Ruling — November 2022
The central legal battle in the Zantac MDL was the admissibility of plaintiffs' general causation expert witnesses — the scientists and physicians whose testimony was intended to establish that ranitidine can cause cancer in humans. In November 2022, Judge Rosenberg issued a comprehensive Daubert ruling that excluded all of plaintiffs' general causation experts for multiple cancer types. The court found that the methodologies used by plaintiffs' experts were scientifically unreliable under the standards set by Daubert v. Merrell Dow Pharmaceuticals (1993) and its federal progeny. Specific criticisms included: (1) reliance on epidemiological studies with fundamental methodological flaws; (2) improper extrapolation from animal studies to human cancer risk; (3) use of unpublished and non-peer-reviewed analyses; and (4) failure to adequately account for confounding variables in population studies. Without admissible general causation experts, plaintiffs could not establish that ranitidine causes cancer at all, let alone in their specific cases. Summary judgment for defendants was therefore granted on all claims in the MDL.
What the MDL Dismissal Does NOT Mean
The November 2022 federal MDL dismissal is frequently misunderstood — and sometimes misrepresented — as establishing that Zantac does not cause cancer, or that all Zantac litigation is over. Neither is correct. The ruling is a federal procedural determination about whether specific expert witnesses, using specific methodologies, satisfied the requirements of the Federal Rules of Evidence in a specific federal court. It has no legal effect on state court claims, which are governed by state procedural rules and state evidentiary standards. State courts are not bound by Judge Rosenberg's rulings, the Federal Rules of Evidence, or the Daubert standard. The Eleventh Circuit's affirmance and the Supreme Court's denial of certiorari likewise apply only to the federal proceedings.
State Courts Apply Different Standards — Why Claims Continue
State courts apply their own evidentiary frameworks for expert testimony. Delaware uses the Frye standard (general acceptance in the relevant scientific community), California uses the Kelly/Frye standard, and most other states use either Daubert or state-specific variations. Under Frye, the question is not whether the individual expert's specific methodology is reliable in the Daubert sense, but whether the scientific community generally accepts the methodology. Plaintiffs' attorneys have also updated and strengthened their expert presentations since the federal MDL, specifically addressing the methodological criticisms raised by Judge Rosenberg and commissioning new peer-reviewed epidemiological analyses. Delaware state court has proceeded to schedule bellwether trials. California courts have denied summary judgment motions in multiple cases. The science has not stopped developing, and the litigation has not ended — it has relocated.
Frequently Asked Questions
Related Pages
Zantac NDMA Contamination Explained
NDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.
The Valisure Study — How the NDMA Problem Was Discovered
Valisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.
Zantac Settlement Expectations — State Court Litigation 2026
Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
Zantac Statute of Limitations — State-by-State 2026 Analysis
The statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
Cancers Covered by Zantac Litigation
Six cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.
Zantac and Bladder Cancer
Bladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
Zantac State Court Litigation — Delaware and California 2026
Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.
Zantac Eligibility Requirements
To qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.
Zantac Brand vs. Generic — All Manufacturers Are Liable
The NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.
FDA Zantac Market Withdrawal — April 2020
On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.
Proving Zantac Use — How to Obtain Pharmacy Records
Pharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
Zantac / Ranitidine (NDMA Cancer) Lawsuit
Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
View full case overview